In November 2022, Eli Lilly and Company began the rollout of its first connected platform, known as the Tempo® Personalized Diabetes Management Platform. It is a technology that aims to assist adults suffering from type 1 diabetes or type 2 diabetes, as well as clinicians, in making treatment decisions supported by data from the company on using Lilly insulins. Smart Button®, an app called TempoSmart™, and Tempo Pen® are three interrelated components that make up the platform, offering individualized guidance to adult diabetics. On September 16th, the Smart Button was given clearance by the US Food and Drug Administration Clearances.
The associated app has been developed with partners like Welldoc®; it is a private-labeled version of BlueStar®, a diabetes management app adapted to receive insulin dose-related data from Tempo Smart Button.
Amazon recently held its long-awaited Devices & Services event for 2023 in September, where it launched several high-tech smart home products that were anticipated by many people. These revolutionary gadgets will be available next month, just in time for shoppers during the holiday season. For product launch, Amazon has planned for the Amazon Early Access Sale next month and the Black Friday sale, which is highly awaited in November. In addition to an impressive array of new hardware, Amazon featured significant improvements to Alexa powered by generative AI. This translates into more natural and engaging conversations with your digital assistant.
Olo introduced Smart Cross-Sells, which will enhance guest engagement and increase average order value within restaurants in April 2024. The feature supports restaurant brands with dynamic, personalized recommendations throughout ordering and checkout. Other features include Order, Pay, and Engage under Olo’s suite of products aimed at increasing orders for restaurants as well as optimizing operations. Olo's Smart Cross-Sells leverage AI to suggest intelligent orders based on factors such as order history menu options at the guest's location, time of day, and items currently in the cart.
Intelligent/smart pill systems are built around the IEM Ingestible Event Markers, which can be mixed into pills or plowed into drugs during manufacturing. In this method, a placebo will be taken with the drug and contain the sensor. Several leading pharmaceutical companies are working to create this structure, which will be made available to those with chronic illnesses. Smart pills are ingestible, capsule-sized medical gadgets with cameras, sensors, patches, and trackers that aid in more accurate diagnosis, patient monitoring, and targeted drug delivery.
They often come in the shape of pills the size of vitamin capsules and have a tiny wearable sensor patch, a smartphone app, and a provider site.
After being ingested, it activates in the stomach; the sensors then offer data on the patient's health conditions and the efficacy of drug treatment, enabling better-informed medical decisions and tailored treatments. Capsule endoscopy is one of several cutting-edge procedures that have emerged due to the high demand for less invasive surgical procedures. Capsule endoscopy is anticipated to displace conventional endoscopic techniques due to benefits including simplicity of administration and thorough viewing of the gastrointestinal tract. Moreover, smart tablets have completely transformed the discipline of gastrointestinal diagnosis.
Being non-invasive, smart tablets can be an effective alternative to invasive procedures like gastrointestinal endoscopy and colonoscopy.
The rise in chronic diseases like cancer, diabetes, and others, as well as the rising prevalence of lifestyle-related illnesses like weight gain, gastroesophageal reflux disease (GERD), ulcers of the stomach, and others, are the main factors driving the growth of the smart pill market. Globally, a growing number of lifestyle-related disorders, including gastrointestinal reflux diseases, gastric ulcers, and others, as well as the increasing incidence of long-term illnesses like colorectal and breast cancer, are some of the key factors predicted to fuel the demand for advanced treatment options.
During the projected period, the market for smart pills is anticipated to rise as patient preferences for minimally invasive treatments for treatment shift. Increased R&D expenditures for creating smart pills also expand the market. The expensive cost of the ingestible sensors and strict government rules regarding the expanding use of these devices are the two reasons that are expected to slow the market's expansion.
Three well-known smart medications, modafinil, dextroamphetamine, and methylphenidate, were the subject of a new study released in Science Advances that looked at how they affected real-world tasks. The theory put up by the researchers was that these medications, which affect norepinephrine and dopamine, would impact effort and motivation, ultimately improving performance.
Key Players for Intelligent Pills Market
Some of the key players in Intelligent Pills market are:
-
CapsoVision, Inc. (US)
- Given Imaging Ltd. (Israel)
- Medimetrics (Mexico)
- (Bio-Images Drug Delivery) BDD LTD (UK)
- Proteus Digital Health (US)\
Intelligent Pills Market Recent Developments
April 2024 : CapsoVision will demonstrate its CapsoCam Plus®, the world’s only small bowel capsule endoscopy system with a 360° panoramic view, at the SGNA 51st Annual Course in Louisville, KY, from May 9–11, 2024. The company will highlight how CapsoCam Plus® improves diagnostic confidence and patient convenience with its unique four-camera design, capturing high-resolution images of the small bowel and any abnormalities. Attendees will have the opportunity to explore how this next-generation system enhances mucosal visibility and enables better detection of lesions.
The integration of advanced technologies in pharmaceuticals is reshaping patient adherence and monitoring, suggesting a transformative shift in healthcare delivery.
U.S. Food and Drug Administration (FDA)
